Laurus Labs Ltd. · NSE:LAURUSLABS
Laurus Labs — Q1 FY2021 Earnings Presentation
25 slides from Laurus Labs's earnings presentation, Jul 30, 2020
Slide 1: Cover letter to stock exchanges
Laurus Labs Limited LAURUS L: Corporate Office T" Floor, Serene Chambers, Road No. 7 Banjara Hills, Hyderabad - 50003^, Telangana, India %^ T +91 W3980^333 / 23^2 0500 / 501 F+91 AO 3980 ^320 Knowledge . Innovation . Excellence July 30, 2020 To To The Corporate Relations Department The Listing Depar
Slide 2: Q1 FY21 Investor Presentation
LAURUS LABS LIMITED Q1 FY21 INVESTOR PRESENTATION July 30, 2020 BSE: 540222 NSE : LAURUSLABS
Slide 3: Disclaimer
Disclaimer This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these
Slide 4: Financial Snapshot – Q1 FY21
Financial Snapshot – Q1 FY21 ₹ Cr Revenue (YoY Gr 77 %) EBITDA (YoY Gr 228%) MARGIN % 29% 974 23% 20% 21% 839 712 729 16% 285 551 193 139 150 87 Q1 FY20 Q2 FY20 Q3 FY20 Q4 FY20 Q1 FY21 Q1 FY20 Q2 FY20 Q3 FY20 Q4 FY20 Q1 FY21 PAT (YoY Gr 1047%) EPS ₹ (YoY Gr 1050%) 172 16.1 110 10.3 74 57 6.9 5.3 15
Slide 5: Business Snapshot
Business Snapshot - API -FDF Overview • Development, manufacture and sale • Developing and manufacturing oral • Contract development and manufacturing services for of APIs and Advanced Intermediates solid formulations for LMIC, North global pharmaceutical companies and several late stage • Leadershi
Slide 6: Segmental Revenue Breakup
Segmental Revenue Breakup ₹ Cr Generics API Generics FDF Synthesis 522 352 467 148 424 292 372 267 359 100 160 85 78 73 106 Q1 Q2 Q3 Q4 Q1 Q1 Q2 Q3 Q4 Q1 Q1 Q2 Q3 Q4 Q1 FY20 FY20 FY20 FY20 FY21 FY20 FY20 FY20 FY20 FY21 FY20 FY20 FY20 FY20 FY21 Q1 FY 21 Contribution • Generic API division showcased a
Slide 7: Generic API Division
Generic API Division ₹ Cr Anti Viral API Onco API Other API 336 60 59 135 317 283 273 51 45 47 98 92 214 90 44 Q1 FY20 Q2 FY20 Q3 FY20 Q4 FY20 Q1 FY21 Q1 FY20 Q2 FY20 Q3 FY20 Q4 FY20 Q1 FY21 Q1 FY20 Q2 FY20 Q3 FY20 Q4 FY20 Q1 FY21 Q1 FY 21 Contribution • Anti Viral API revenue showed a growth of 19%
Slide 8: Generic FDF Division
Generic FDF Division ₹ Cr Generic FDF 352 292 267 160 106 Q1 FY20 Q2 FY20 Q3 FY20 Q4 FY20 Q1 FY21 Generic FDF revenue showcased a robust growth of 232% YoY • RoW Markets – Received approvals for TLE400 and TLE600 from the US FDA • North America – Sales were driven by launch of HCQ in US and increase
Slide 9: Synthesis (CDMO) Division
Synthesis (CDMO) Division ₹ Cr Synthesis Revenue 148 100 85 78 73 Q1 FY20 Q2 FY20 Q3 FY20 Q4 FY20 Q1 FY21 • Revenue from Custom Synthesis division showed a growth of 37% (YoY) • Total Number of Active Projects in the CDMO division stood at 47 as on Q1 FY21 • Incorporated Wholly Owned Subsidiary to g
Slide 10: 5 year Division wise Revenue Contribution
5 year Division wise Revenue Contribution 7% 9% 2% 10% 3% 13% 8% 8% 8% 29% 6% 9% 36% 8% 10% 14% 10% 11% 15% 82% 7% 77% 74% 5% 66% 39% 34% FY 16 FY 17 FY 18 FY 19 FY 20 FY 21 Q1 Anti Viral API Onco API Other API Custom Synthesis Generic FDF 9
Slide 11: 5 years Return Ratios
5 years Return Ratios Pre Tax Return on Capital Return on Equity(2) (%) Total Debt/Equity Ratio (x) Employed(1) (%) 37.0% 0.7x 0.7x 32.3% 0.6x 0.6x 0.6x 16.5% 17.4% 13.7% 14.1% 15.3% 11.9% 8.2% 6.2% FY17 FY 18 FY 19 FY 20 Q1 FY21 FY17 FY 18 FY 19 FY 20 Q1 FY21 FY17 FY 18 FY 19 FY 20 Q1 FY21 Note: Ba
Slide 12: COVID – 19 Response
COVID – 19 Response National lockdown has resulted in a temporary slow down of operations but Laurus Labs has quickly restored normalcy in production and services with rigorous safety, hygiene and cleaning protocols at all our manufacturing facilities, R&D Center and Corporate Office. Work from Home
Slide 13: Manufacturing Facilities at Parawada, Vizag
Manufacturing Facilities at Parawada, Vizag Unit-I • Located at Jawaharlal Nehru Pharma City, Vishakhapatnam, India. • API manufacturing facility and includes capacity for ingredients, synthesis and contract manufacturing. • Commenced operations in 2007. • 323 reactors with 1,196 Kilo Liters capacit
Slide 14: Manufacturing Facilities at Achutapuram, Vizag
Manufacturing Facilities at Achutapuram, Vizag • Located at APIIC, Achutapuram, Visakhapatnam, India. (SEZ) Unit-II • FDF and API manufacturing facility • Commenced operations in 2017. • FDF - capacity of 5 bn tablets/capsules per year. Capacity expansion initiated and will be operational by Septemb
Slide 15: Quality Focus & Regulatory Audits
Quality Focus & Regulatory Audits Facility Key Agencies Recent Inspection Year Kilo Lab – R&D USFDA 2016 – EIR received USFDA, WHO – Geneva, ANVISA, 2019 – EIR Received, Unit 1 COFEPRIS – Mexico and JZAMP – and cGMP certification received Slovenia USFDA, WHO – Geneva, BGV Hamburg, 2019 – EIR Receive
Slide 16: Strong R&D Capabilities
Strong R&D Capabilities R&D Centre - Hyd 166 160 134 114 85 7.4% 7.1% 5.6% 5.7% 42 4.8% 4.3% FY16 FY17 FY18 FY 19 FY 20 FY 21 Q1 R&D Spend ₹ Cr % of Revenue Current Filings Status Therapy US ANDA Europe Canada Patents Patents ARV 15 4 5 DMFs Filed Granted Anti- Diabetic 3 3 2 Cumulative CVS 3 - - Fi
Slide 17: Outlook for FY21 & Beyond
Outlook for FY21 & Beyond Healthy Revenue visibility on the Changing business mix to drive Capacity augmentation to result back of robust Order Book growth in better return ratios • Partnership with Global Fund offers higher • Generic FDF segment contributed ~36% • Among top 5 in India in terms of v
Slide 18: Key Milestones
Key Milestones • Investment of INR 3000 mn by • Investment of INR Warburg Pincus • Crossed INR 20 billion of revenue 600 mn by FIL • Incorporated First • Commenced commercial operations • Set up the R&D Capital Subsidiary in USA. • Successfully listed on BSE &NSE from Unit 4 Centre at IKP, Managemen
Slide 19: Management Team
Management Team Dr. Satyanarayana Chava Mr V.V Ravi Kumar Dr. Lakshmana Rao C V Dr. V Uma Maheswer Rao Mr. S. Srinivasa Rao Founder & CEO ED & CFO ED & Head, Quality Exec. VP & Head, Chemical Exec. VP – Operations R&D Mr. Krishna Chaitanya Chava Mr. Tom Versosky Dr. Prafulla Kumar Nandi Mr. Martyn P
Slide 20: Corporate Governance
Corporate Governance Executive Directors Name Background Dr Satyanarayana Chava Whole-time Director, Founder and Chief Executive Officer Ravi Kumar V V Whole-time Director and CFO Dr Lakshmana Rao C V Whole-time Director and Head, Quality Non-Executive Directors Name Background Dr. M. Venu Gop
Slide 21: Ownership Structure
Ownership Structure Corporate Structure All are 100% Subsidiaries Laurus Labs Limited India Laurus Synthesis Sriam Labs Pvt Ltd. Laurus Holdings Ltd. Laurus Synthesis Laurus Generics SA Inc. India UK Pvt. Ltd (PTY) Limited USA Laurus Generics Laurus Generics Inc. GmbH. USA Germany Shareholding patte
Slide 22: Awards 2019-20
Awards 2019 -20 PORTER PRIZE 2019 Laurus Labs won the prestigious Porter Prize 2019. The eponymous award was presented to Dr. Satyanarayana Chava, Founder & CEO, Laurus Labs, by Dr. Bibek Debroy, Chairman of the Economic Advisory Council to the Prime Minister (EAC-PM), while Prof. Michael E. Porter,
Slide 23: Results Conference Call
Results Conference Call Results conference call on Friday July 31, 2020 at 11:00 AM IST Details of the conference call are as follows: Timing 11:00 am IST on Friday, July 31, 2020 Conference dial-in Universal Dial-In +91 22 6280 1214 India Local access Number +91 7045671221 Available all over India
Slide 24: Contact us
Contact us About Laurus Labs Ltd. Laurus Labs is a leading research driven Pharmaceutical manufacturing Company in India. We have grown to become one of the leading manufacturers of API for Anti-Retroviral (ARV), Oncology, Cardiovascular, Anti-Diabetics, Anti-Asthma and Gastroenterology .We are thri
Slide 25: Thank You
Thank You